Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis

Cancer and Metastasis Reviews

Volumn 34, Issue 4, 2015, Pages 575-591

  Schlesinger, Martin ^a   Bendas, Gerd ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Angiogenesis; Cancer; Integrin; Metastasis; VCAM 1; VLA 4

Indexed keywords

VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESEARCH; DRUG RESISTANCE; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; IMMUNOSURVEILLANCE; LEUKOCYTE; LYMPHANGIOGENESIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; CELL ADHESION; CELL MOTION; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TUMOR MICROENVIRONMENT;

CELL ADHESION; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; HUMANS; INTEGRIN ALPHA4BETA1; LEUKOCYTES; LYMPHANGIOGENESIS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84958942681     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-014-9545-x     Document Type: Article

References (236)

1. Hemler, M. E. (1990). VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annual Review of Immunology, 8, 365–400.
2. Kinashi, T. (2005). Intracellular signalling controlling integrin activation in lymphocytes. Nature Reviews Immunology, 5(7), 546–559.
3. Phillips, D. R., Fitzgerald, L. A., Charo, I. F., & Parise, L. V. (1987). The platelet membrane glycoprotein IIb/IIIa complex. Structure, function, and relationship to adhesive protein receptors in nucleated cells. Annals of the New York Academy of Sciences, 509, 177–187.
4. Phillips, D. R., Charo, I. F., Parise, L. V., & Fitzgerald, L. A. (1988). The platelet membrane glycoprotein IIb-IIIa complex. Blood, 71(4), 831–843.
5. Byron, A., Humphries, J. D., Craig, S. E., Knight, D., & Humphries, M. J. (2012). Proteomic analysis of α4β1 integrin adhesion complexes reveals α-subunit-dependent protein recruitment. Proteomics, 12(13), 2107–2114.
6. Humphries, J. D., Byron, A., & Humphries, M. J. (2006). Integrin ligands at a glance. Journal of Cell Science, 119(Pt 19), 3901–3903.
7. Luo, B.-H., & Springer, T. A. (2006). Integrin structures and conformational signaling. Current Opinion in Cell Biology, 18(5), 579–586.
8. Takada, Y., Strominger, J. L., & Hemler, M. E. (1987). The very late antigen family of heterodimers is part of a superfamily of molecules involved in adhesion and embryogenesis. Proceedings of the National Academy of Sciences of the United States of America, 84(10), 3239–3243.
9. Takada, Y., Ye, X., & Simon, S. (2007). The integrins. Genome Biology, 8(5), 215.
10. Hynes, R. O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell, 110(6), 673–687.
11. Yang, J. T., Rayburn, H., & Hynes, R. O. (1995). Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development (Cambridge, England), 121(2), 549–560.
12. Luo, B.-H., Carman, C. V., & Springer, T. A. (2007). Structural basis of integrin regulation and signaling. Annual Review of Immunology, 25, 619–647.
13. Bayless, K. J., Meininger, G. A., Scholtz, J. M., & Davis, G. E. (1998). Osteopontin is a ligand for the alpha4beta1 integrin. Journal of Cell Science, 111(Pt 9), 1165–1174.
14. Clements, J. M., Newham, P., Shepherd, M., Gilbert, R., Dudgeon, T. J., Needham, L. A., & Humphries, M. J. (1994). Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin. Journal of Cell Science, 107(Pt 8), 2127–2135.
15. Hemler, M. E., Huang, C., & Schwarz, L. (1987). The VLA protein family. Characterization of five distinct cell surface heterodimers each with a common 130,000 molecular weight beta subunit. The Journal of Biological Chemistry, 262(7), 3300–3309.
16. Hemler, M. E., Huang, C., Takada, Y., Schwarz, L., Strominger, J. L., & Clabby, M. L. (1987). Characterization of the cell surface heterodimer VLA-4 and related peptides. The Journal of Biological Chemistry, 262(24), 11478–11485.
17. Takada, Y., Elices, M. J., Crouse, C., & Hemler, M. E. (1989). The primary structure of the alpha 4 subunit of VLA-4: homology to other integrins and a possible cell-cell adhesion function. The EMBO Journal, 8(5), 1361–1368.
18. Chigaev, A., & Sklar, L. A. (2012). Aspects of VLA-4 and LFA-1 regulation that may contribute to rolling and firm adhesion. Frontiers in Immunology, 3, 242.
19. Elices, M. J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M. E., & Lobb, R. R. (1990). VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell, 60(4), 577–584.
20. Shimizu, Y., van Seventer, G. A., Horgan, K. J., & Shaw, S. (1990). Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. Journal of Immunology, 145(1), 59–67.
21. Bridges, L. C., Sheppard, D., & Bowditch, R. D. (2005). ADAM disintegrin-like domain recognition by the lymphocyte integrins alpha4beta1 and alpha4beta7. The Biochemical Journal, 387(Pt 1), 101–108.
22. Humphries, J. D., & Humphries, M. J. (2007). CD14 is a ligand for the integrin alpha4beta1. FEBS Letters, 581(4), 757–763.
23. El Nemer, W., Wautier, M.-P., Rahuel, C., Gane, P., Hermand, P., Galactéros, F., & Le Van Kim, C. (2007). Endothelial Lu/BCAM glycoproteins are novel ligands for red blood cell alpha4beta1 integrin: role in adhesion of sickle red blood cells to endothelial cells. Blood, 109(8), 3544–3551.
24. Huang, J., Filipe, A., Rahuel, C., Bonnin, P., Mesnard, L., Guérin, C., & Tharaux, P.-L. (2014). Lutheran/basal cell adhesion molecule accelerates progression of crescentic glomerulonephritis in mice. Kidney International, 85(5), 1123–1136.
25. Yang, Y., Harrison, J. E., Print, C. G., Lehnert, K., Sammar, M., Lazarovits, A., & Krissansen, G. W. (1996). Interaction of monocytoid cells with the mucosal addressin MAdCAM-1 via the integrins VLA-4 and LPAM-1. Immunology and Cell Biology, 74(5), 383–393.
26. Lehnert, K., Print, C. G., Yang, Y., & Krissansen, G. W. (1998). MAdCAM-1 costimulates T cell proliferation exclusively through integrin alpha4beta7, whereas VCAM-1 and CS-1 peptide use alpha4beta1: evidence for “remote” costimulation and induction of hyperresponsiveness to B7 molecules. European Journal of Immunology, 28(11), 3605–3615.
27. Berlin, C., Berg, E. L., Briskin, M. J., Andrew, D. P., Kilshaw, P. J., Holzmann, B., & Butcher, E. C. (1993). Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell, 74(1), 185–195.
28. Alon, R., Kassner, P. D., Carr, M. W., Finger, E. B., Hemler, M. E., & Springer, T. A. (1995). The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. The Journal of Cell Biology, 128(6), 1243–1253.
29. Berlin, C., Bargatze, R. F., Campbell, J. J., von Andrian, U. H., Szabo, M. C., Hasslen, S. R., & Butcher, E. C. (1995). Alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell, 80(3), 413–422.
30. Chen, C., Mobley, J. L., Dwir, O., Shimron, F., Grabovsky, V., Lobb, R. R., & Alon, R. (1999). High affinity very late antigen-4 subsets expressed on T cells are mandatory for spontaneous adhesion strengthening but not for rolling on VCAM-1 in shear flow. Journal of immunology (Baltimore, Md.: 1950), 162(2), 1084–1095.
31. Grabovsky, V., Feigelson, S., Chen, C., Bleijs, D. A., Peled, A., Cinamon, G., & Alon, R. (2000). Subsecond induction of alpha4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions. The Journal of Experimental Medicine, 192(4), 495–506.
32. Ding, Z., Xiong, K., & Issekutz, T. B. (2001). Chemokines stimulate human T lymphocyte transendothelial migration to utilize VLA-4 in addition to LFA-1. Journal of Leukocyte Biology, 69(3), 458–466.
33. Nguyen, K., Sylvain, N. R., & Bunnell, S. C. (2008). T cell costimulation via the integrin VLA-4 inhibits the actin-dependent centralization of signaling microclusters containing the adaptor SLP-76. Immunity, 28(6), 810–821.
34. Burkhardt, J. K. (2008). Integrins put the brakes on microcluster dynamics at the immunological synapse. Immunity, 28(6), 732–734.
35. Carrasco, Y. R., & Batista, F. D. (2006). B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 with VCAM-1. The EMBO Journal, 25(4), 889–899.
36. Wang, Q.-Q., Li, H., Oliver, T., Glogauer, M., Guo, J., & He, Y.-W. (2008). Integrin beta 1 regulates phagosome maturation in macrophages through Rac expression. Journal of Immunology (Baltimore, Md.: 1950), 180(4), 2419–2428.
37. Milner, R., & Campbell, I. L. (2002). Developmental regulation of beta1 integrins during angiogenesis in the central nervous system. Molecular and Cellular Neurosciences, 20(4), 616–626.
38. Lawrence, M. B., & Springer, T. A. (1991). Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell, 65(5), 859–873.
39. Von Andrian, U. H., Chambers, J. D., McEvoy, L. M., Bargatze, R. F., Arfors, K. E., & Butcher, E. C. (1991). Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte beta 2 integrins in vivo. Proceedings of the National Academy of Sciences of the United States of America, 88(17), 7538–7542.
40. Masumoto, A., & Hemler, M. E. (1993). Multiple activation states of VLA-4. Mechanistic differences between adhesion to CS1/fibronectin and to vascular cell adhesion molecule-1. The Journal of Biological Chemistry, 268(1), 228–234.
41. Chigaev, A., Waller, A., Zwartz, G. J., Buranda, T., & Sklar, L. A. (2007). Regulation of cell adhesion by affinity and conformational unbending of alpha4beta1 integrin. Journal of Immunology, 178(11), 6828–6839.
42. Chigaev, A., Waller, A., Amit, O., Halip, L., Bologa, C. G., & Sklar, L. A. (2009). Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation. The Journal of Biological Chemistry, 284(21), 14337–14346.
43. Zwartz, G. J., Chigaev, A., Dwyer, D. C., Foutz, T. D., Edwards, B. S., & Sklar, L. A. (2004). Real-time analysis of very late antigen-4 affinity modulation by shear. The Journal of Biological Chemistry, 279(37), 38277–38286.
44. Chigaev, A., Waller, A., Amit, O., & Sklar, L. A. (2008). Galphas-coupled receptor signaling actively down-regulates alpha4beta1-integrin affinity: a possible mechanism for cell de-adhesion. BMC Immunology, 9, 26.
45. Chigaev, A., Smagley, Y., & Sklar, L. A. (2011). Nitric oxide/cGMP pathway signaling actively down-regulates α4β1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion. BMC Immunology, 12, 28.
46. Fujita, M., Takada, Y. K., Izumiya, Y., & Takada, Y. (2014). The binding of monomeric C-reactive protein (mCRP) to Integrins αvβ3 and α4β1 is related to its pro-inflammatory action. PLoS ONE, 9(4), e93738.
47. Schmitz, P., Gerber, U., Schütze, N., Jüngel, E., Blaheta, R., Naggi, A., & Bendas, G. (2013). Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4. Thrombosis and Haemostasis, 110(5), 1046–1054.
48. Fujita, M., Takada, Y. K., & Takada, Y. (2014). The chemokine fractalkine can activate integrins without CX3CR1 through direct binding to a ligand-binding site distinct from the classical RGD-binding site. PLoS ONE, 9(5), e96372.
49. Fiorcari, S., Brown, W. S., McIntyre, B. W., Estrov, Z., Maffei, R., O’Brien, S., & Burger, J. A. (2013). The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS ONE, 8(12), e83830.
50. Schmid, M. C., Franco, I., Kang, S. W., Hirsch, E., Quilliam, L. A., & Varner, J. A. (2013). PI3-kinase γ promotes Rap1a-mediated activation of myeloid cell integrin α4β1, leading to tumor inflammation and growth. PLoS ONE, 8(4), e60226.
51. Feigelson, S. W., Grabovsky, V., Winter, E., Chen, L. L., Pepinsky, R. B., Yednock, T., & Alon, R. (2001). The Src kinase p56(lck) up-regulates VLA-4 integrin affinity. Implications for rapid spontaneous and chemokine-triggered T cell adhesion to VCAM-1 and fibronectin. The Journal of Biological Chemistry, 276(17), 13891–13901.
52. Brown, W. S., Khalili, J. S., Rodriguez-Cruz, T. G., Lizee, G., & McIntyre, B. W. (2014). B-Raf regulation of integrin α4β1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells. The Journal of Biological Chemistry. doi:10.1074/jbc.M114.562918.
53. De Bruyn, K. M. T., Rangarajan, S., Reedquist, K. A., Figdor, C. G., & Bos, J. L. (2002). The small GTPase Rap1 is required for Mn(2+)- and antibody-induced LFA-1- and VLA-4-mediated cell adhesion. The Journal of Biological Chemistry, 277(33), 29468–29476.
54. Sánchez-Mateos, P., Campanero, M. R., Balboa, M. A., & Sánchez-Madrid, F. (1993). Co-clustering of beta 1 integrins, cytoskeletal proteins, and tyrosine-phosphorylated substrates during integrin-mediated leukocyte aggregation. Journal of Immunology, 151(7), 3817–3828.
55. Alon, R., Feigelson, S. W., Manevich, E., Rose, D. M., Schmitz, J., Overby, D. R., & Ginsberg, M. H. (2005). Alpha4beta1-dependent adhesion strengthening under mechanical strain is regulated by paxillin association with the alpha4-cytoplasmic domain. The Journal of Cell Biology, 171(6), 1073–1084.
56. Manevich, E., Grabovsky, V., Feigelson, S. W., & Alon, R. (2007). Talin 1 and paxillin facilitate distinct steps in rapid VLA-4-mediated adhesion strengthening to vascular cell adhesion molecule 1. The Journal of Biological Chemistry, 282(35), 25338–25348.
57. Hyduk, S. J., Rullo, J., Cano, A. P., Xiao, H., Chen, M., Moser, M., & Cybulsky, M. I. (2011). Talin-1 and kindlin-3 regulate alpha4beta1 integrin-mediated adhesion stabilization, but not G protein-coupled receptor-induced affinity upregulation. Journal of Immunology, 187(8), 4360–4368.
58. Poste, G., & Fidler, I. J. (1980). The pathogenesis of cancer metastasis. Nature, 283(5743), 139–146.
59. Rice, G. E., Gimbrone, M. A., Jr., & Bevilacqua, M. P. (1988). Tumor cell-endothelial interactions. Increased adhesion of human melanoma cells to activated vascular endothelium. The American Journal of Pathology, 133(2), 204–210.
60. Rice, G. E., & Bevilacqua, M. P. (1989). An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science, 246(4935), 1303–1306.
61. Taichman, D. B., Cybulsky, M. I., Djaffar, I., Longenecker, B. M., Teixidó, J., Rice, G. E., & Bevilacqua, M. P. (1991). Tumor cell surface alpha 4 beta 1 integrin mediates adhesion to vascular endothelium: demonstration of an interaction with the N-terminal domains of INCAM-110/VCAM-1. Cell Regulation, 2(5), 347–355.
62. Juneja, H. S., Schmalsteig, F. C., Lee, S., & Chen, J. (1993). Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells. Experimental Hematology, 21(3), 444–450.
63. Csanaky, G., Matutes, E., Vass, J. A., Morilla, R., & Catovsky, D. (1997). Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias. Leukemia, 11(3), 408–415.
64. Martìn-Padura, I., Mortarini, R., Lauri, D., Bernasconi, S., Sanchez-Madrid, F., Parmiani, G., & Dejana, E. (1991). Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression. Cancer Research, 51(8), 2239–2241.
65. Zhu, N. W., Perks, C. M., Burd, A. R., & Holly, J. M. (1999). Changes in the levels of integrin and focal adhesion kinase (FAK) in human melanoma cells following 532 nm laser treatment. International Journal of Cancer. Journal International Du Cancer, 82(3), 353–358.
66. Zhu, N., Eves, P. C., Katerinaki, E., Szabo, M., Morandini, R., Ghanem, G., & Haycock, J. W. (2002). Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone. The Journal of Investigative Dermatology, 119(5), 1165–1171.
67. Klemke, M., Weschenfelder, T., Konstandin, M. H., & Samstag, Y. (2007). High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. Journal of Cellular Physiology, 212(2), 368–374.
68. Okahara, H., Yagita, H., Miyake, K., & Okumura, K. (1994). Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor alpha enhancement of experimental metastasis. Cancer Research, 54(12), 3233–3236.
69. Garofalo, A., Chirivi, R. G., Foglieni, C., Pigott, R., Mortarini, R., Martin-Padura, I., & Dejana, E. (1995). Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Research, 55(2), 414–419.
70. Higashiyama, A., Watanabe, H., Okumura, K., & Yagita, H. (1996). Involvement of tumor necrosis factor alpha and very late activation antigen 4/vascular cell adhesion molecule 1 interaction in surgical-stress-enhanced experimental metastasis. Cancer Immunology, Immunotherapy: CII, 42(4), 231–236.
71. Cardones, A. R., Murakami, T., & Hwang, S. T. (2003). CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Research, 63(20), 6751–6757.
72. Rebhun, R. B., Cheng, H., Gershenwald, J. E., Fan, D., Fidler, I. J., & Langley, R. R. (2010). Constitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. Neoplasia, 12(2), 173–182.
73. Khatib, A.-M., Auguste, P., Fallavollita, L., Wang, N., Samani, A., Kontogiannea, M., & Brodt, P. (2005). Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. The American Journal of Pathology, 167(3), 749–759.
74. Sipos, E., Chen, L., András, I. E., Wrobel, J., Zhang, B., Pu, H., & Toborek, M. (2012). Proinflammatory adhesion molecules facilitate polychlorinated biphenyl-mediated enhancement of brain metastasis formation. Toxicological Sciences, 126(2), 362–371.
75. Langley, R. R., Carlisle, R., Ma, L., Specian, R. D., Gerritsen, M. E., & Granger, D. N. (2001). Endothelial expression of vascular cell adhesion molecule-1 correlates with metastatic pattern in spontaneous melanoma. Microcirculation, 8(5), 335–345.
76. Haddad, O., Chotard-Ghodsnia, R., Verdier, C., & Duperray, A. (2010). Tumor cell/endothelial cell tight contact upregulates endothelial adhesion molecule expression mediated by NFkappaB: differential role of the shear stress. Experimental Cell Research, 316(4), 615–626.
77. Chiu, J.-J., Chen, L.-J., Lee, P.-L., Lee, C.-I., Lo, L.-W., Usami, S., & Chien, S. (2003). Shear stress inhibits adhesion molecule expression in vascular endothelial cells induced by coculture with smooth muscle cells. Blood, 101(7), 2667–2674.
78. Chiu, J.-J., Lee, P.-L., Chen, C.-N., Lee, C.-I., Chang, S.-F., Chen, L.-J., & Chien, S. (2004). Shear stress increases ICAM-1 and decreases VCAM-1 and E-selectin expressions induced by tumor necrosis factor-[alpha] in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(1), 73–79.
79. Partridge, J., Carlsen, H., Enesa, K., Chaudhury, H., Zakkar, M., Luong, L., & Evans, P. C. (2007). Laminar shear stress acts as a switch to regulate divergent functions of NF-kappaB in endothelial cells. FASEB Journal, 21(13), 3553–3561.
80. Qian, F., Vaux, D. L., & Weissman, I. L. (1994). Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell, 77(3), 335–347.
81. Johnson, J. P. (1999). Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Reviews, 18(3), 345–357.
82. Huhtala, P., Humphries, M. J., McCarthy, J. B., Tremble, P. M., Werb, Z., & Damsky, C. H. (1995). Cooperative signaling by alpha 5 beta 1 and alpha 4 beta 1 integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. The Journal of Cell Biology, 129(3), 867–879.
83. Altevogt, P., Hubbe, M., Ruppert, M., Lohr, J., von Hoegen, P., Sammar, M., & Butcher, E. C. (1995). The alpha 4 integrin chain is a ligand for alpha 4 beta 7 and alpha 4 beta 1. The Journal of Experimental Medicine, 182(2), 345–355.
84. Campanero, M. R., Arroyo, A. G., Pulido, R., Ursa, A., de Matías, M. S., Sánchez-Mateos, P., & Corbí, A. L. (1992). Functional role of alpha 2/beta 1 and alpha 4/beta 1 integrins in leukocyte intercellular adhesion induced through the common beta 1 subunit. European Journal of Immunology, 22(12), 3111–3119.
85. Bednarczyk, J. L., & McIntyre, B. W. (1990). A monoclonal antibody to VLA-4 alpha-chain (CDw49d) induces homotypic lymphocyte aggregation. Journal of Immunology, 144(3), 777–784.
86. Bednarczyk, J. L., Wygant, J. N., Szabo, M. C., Molinari-Storey, L., Renz, M., Fong, S., & McIntyre, B. W. (1993). Homotypic leukocyte aggregation triggered by a monoclonal antibody specific for a novel epitope expressed by the integrin beta 1 subunit: conversion of nonresponsive cells by transfecting human integrin alpha 4 subunit cDNA. Journal of Cellular Biochemistry, 51(4), 465–478.
87. Pulido, R., Elices, M. J., Campanero, M. R., Osborn, L., Schiffer, S., García-Pardo, A., & Sánchez-Madrid, F. (1991). Functional evidence for three distinct and independently inhibitable adhesion activities mediated by the human integrin VLA-4. Correlation with distinct alpha 4 epitopes. The Journal of Biological Chemistry, 266(16), 10241–10245.
88. Hart, I. R., Birch, M., & Marshall, J. F. (1991). Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Reviews, 10(2), 115–128.
89. Moretti, S., Martini, L., Berti, E., Pinzi, C., & Giannotti, B. (1993). Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Research, 3(4), 235–239.
90. Schadendorf, D., Gawlik, C., Haney, U., Ostmeier, H., Suter, L., & Czarnetzki, B. M. (1993). Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. The Journal of Pathology, 170(4), 429–434.
91. Schadendorf, D., Heidel, J., Gawlik, C., Suter, L., & Czarnetzki, B. M. (1995). Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. Journal of the National Cancer Institute, 87(5), 366–371.
92. Chen, Q., Zhang, X. H.-F., & Massagué, J. (2011). Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell, 20(4), 538–549.
93. Lin, K.-Y., Lu, D., Hung, C.-F., Peng, S., Huang, L., Jie, C., & Wu, T.-C. (2007). Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Research, 67(4), 1832–1841.
94. Kuai, W.-X., Wang, Q., Yang, X.-Z., Zhao, Y., Yu, R., & Tang, X.-J. (2012). Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells. World Journal of Gastroenterology: WJG, 18(9), 979–985.
95. Ruco, L. P., de Laat, P. A., Matteucci, C., Bernasconi, S., Sciacca, F. M., van der Kwast, T. H., & Versnel, M. A. (1996). Expression of ICAM-1 and VCAM-1 in human malignant mesothelioma. The Journal of Pathology, 179(3), 266–271.
96. Ding, Y.-B., Chen, G.-Y., Xia, J.-G., Zang, X.-W., Yang, H.-Y., & Yang, L. (2003). Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World Journal of Gastroenterology: WJG, 9(7), 1409–1414.
97. Gupta, G. P., Minn, A. J., Kang, Y., Siegel, P. M., Serganova, I., Cordón-Cardo, C., & Massagué, J. (2005). Identifying site-specific metastasis genes and functions. Cold Spring Harbor Symposia on Quantitative Biology, 70, 149–158.
98. Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., & Massagué, J. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436(7050), 518–524.
99. Vanharanta, S., & Massagué, J. (2013). Origins of metastatic traits. Cancer Cell, 24(4), 410–421.
100. Chen, Q., & Massagué, J. (2012). Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clinical Cancer Research, 18(20), 5520–5525.
101. Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., & Kang, Y. (2011). VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell, 20(6), 701–714.
102. Hynes, R. O. (2011). Metastatic cells will take any help they can get. Cancer Cell, 20(6), 689–690.
103. Lin, K. Y., Guarnieri, F. G., Staveley-O’Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., & Wu, T. C. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Research, 56(1), 21–26.
104. Wu, T. C., Guarnieri, F. G., Staveley-O’Carroll, K. F., Viscidi, R. P., Levitsky, H. I., Hedrick, L., & Pardoll, D. M. (1995). Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proceedings of the National Academy of Sciences of the United States of America, 92(25), 11671–11675.
105. Wu, T.-C. (2007). The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Research, 67(13), 6003–6006.
106. Rose, D. M., Grabovsky, V., Alon, R., & Ginsberg, M. H. (2001). The affinity of integrin alpha(4)beta(1) governs lymphocyte migration. Journal of Immunology, 167(5), 2824–2830.
107. Rose, D. M., Han, J., & Ginsberg, M. H. (2002). Alpha4 integrins and the immune response. Immunological Reviews, 186, 118–124.
108. Liu, S., Thomas, S. M., Woodside, D. G., Rose, D. M., Kiosses, W. B., Pfaff, M., & Ginsberg, M. H. (1999). Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses. Nature, 402(6762), 676–681.
109. Rose, D. M., Liu, S., Woodside, D. G., Han, J., Schlaepfer, D. D., & Ginsberg, M. H. (2003). Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. Journal of Immunology, 170(12), 5912–5918.
110. Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., & Lyden, D. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069), 820–827.
111. Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., & Zlotnik, A. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50–56.
112. Zlotnik, A., Burkhardt, A. M., & Homey, B. (2011). Homeostatic chemokine receptors and organ-specific metastasis. Nature Reviews Immunology, 11(9), 597–606.
113. Williams, S. A., Harata-Lee, Y., Comerford, I., Anderson, R. L., Smyth, M. J., & McColl, S. R. (2010). Multiple functions of CXCL12 in a syngeneic model of breast cancer. Molecular Cancer, 9, 250.
114. Koizumi, K., Kozawa, Y., Ohashi, Y., Nakamura, E. S., Aozuka, Y., Sakurai, H., & Saiki, I. (2007). CCL21 promotes the migration and adhesion of highly lymph node metastatic human non-small cell lung cancer Lu-99 in vitro. Oncology Reports, 17(6), 1511–1516.
115. Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S., & Ruco, L. (1992). The origin and function of tumor-associated macrophages. Immunology Today, 13(7), 265–270.
116. Conti, I., & Rollins, B. J. (2004). CCL2 (monocyte chemoattractant protein-1) and cancer. Seminars in Cancer Biology, 14(3), 149–154.
117. Zhao, L., Lim, S. Y., Gordon-Weeks, A. N., Tapmeier, T. T., Im, J. H., Cao, Y., & Muschel, R. J. (2013). Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology, 57(2), 829–839.
118. Lim, S. Y., Gordon-Weeks, A. N., Zhao, L., Tapmeier, T. T., Im, J. H., Cao, Y., & Muschel, R. J. (2013). Recruitment of myeloid cells to the tumor microenvironment supports liver metastasis. Oncoimmunology, 2(3), e23187.
119. Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., & Pollard, J. W. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475(7355), 222–225.
120. Qian, B., Deng, Y., Im, J. H., Muschel, R. J., Zou, Y., Li, J., & Pollard, J. W. (2009). A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PloS One, 4(8), e6562.
121. Gil-Bernabé, A. M., Ferjancic, S., Tlalka, M., Zhao, L., Allen, P. D., Im, J. H., & Muschel, R. J. (2012). Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood, 119(13), 3164–3175.
122. Ferjancic, S., Gil-Bernabé, A. M., Hill, S. A., Allen, P. D., Richardson, P., Sparey, T., & Muschel, R. J. (2013). VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice. Blood, 121(16), 3289–3297.
123. Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008). The role of myeloid cells in the promotion of tumour angiogenesis. Nature Reviews Cancer, 8(8), 618–631.
124. Tazzyman, S., Lewis, C. E., & Murdoch, C. (2009). Neutrophils: key mediators of tumour angiogenesis. International Journal of Experimental Pathology, 90(3), 222–231.
125. Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013). The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology, 138(2), 105–115.
126. Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., & Lin, P. C. (2004). Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6(4), 409–421.
127. Jin, H., Su, J., Garmy-Susini, B., Kleeman, J., & Varner, J. (2006). Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Research, 66(4), 2146–2152.
128. Joshi, S., Singh, A. R., Zulcic, M., Bao, L., Messer, K., Ideker, T., & Durden, D. L. (2014). Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PLoS ONE, 9(4), e95893.
129. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine, 285(21), 1182–1186.
130. Ide, A. G., Baker, N. H., & Warren, S. L. (1939). Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. American Journal of Roentgenology, 42, 891–899.
131. Algire, G. H., Chalkley, H. W., Legallais, F. Y., & Park, H. D. (1945). Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. Journal of the National Cancer Institute, 6(1), 73–85.
132. Folkman, J., Merler, E., Abernathy, C., & Williams, G. (1971). Isolation of a tumor factor responsible for angiogenesis. The Journal of Experimental Medicine, 133(2), 275–288.
133. Gimbrone, M. A., Jr., Leapman, S. B., Cotran, R. S., & Folkman, J. (1972). Tumor dormancy in vivo by prevention of neovascularization. The Journal of Experimental Medicine, 136(2), 261–276.
134. Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008). Integrins in angiogenesis and lymphangiogenesis. Nature Reviews Cancer, 8(8), 604–617.
135. Garmy-Susini, B., & Varner, J. A. (2008). Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphatic Research and Biology, 6(3–4), 155–163.
136. Grant, M. B., May, W. S., Caballero, S., Brown, G. A. J., Guthrie, S. M., Mames, R. N., & Scott, E. W. (2002). Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nature Medicine, 8(6), 607–612.
137. Patterson, L. J., Gering, M., & Patient, R. (2005). Scl is required for dorsal aorta as well as blood formation in zebrafish embryos. Blood, 105(9), 3502–3511.
138. Wang, L., Li, L., Shojaei, F., Levac, K., Cerdan, C., Menendez, P., & Bhatia, M. (2004). Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity, 21(1), 31–41.
139. Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., & Rafii, S. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Medicine, 7(11), 1194–1201.
140. Chen, L., Ackerman, R., Saleh, M., Gotlinger, K. H., Kessler, M., Mendelowitz, L. G., & Guo, A. M. (2014). 20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo. The Journal of Pharmacology and Experimental Therapeutics, 348(3), 442–451.
141. Jin, H., Aiyer, A., Su, J., Borgstrom, P., Stupack, D., Friedlander, M., & Varner, J. (2006). A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. The Journal of Clinical Investigation, 116(3), 652–662.
142. Schmid, M. C., & Varner, J. A. (2009). Circulating endothelial progenitor cells. Methods in Molecular Biology, 467, 139–155.
143. Ruzinova, M. B., Schoer, R. A., Gerald, W., Egan, J. E., Pandolfi, P. P., Rafii, S., & Benezra, R. (2003). Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell, 4(4), 277–289.
144. Ono, M., Torisu, H., Fukushi, J., Nishie, A., & Kuwano, M. (1999). Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemotherapy and Pharmacology, 43(Suppl), S69–71.
145. Jin, D. K., Shido, K., Kopp, H.-G., Petit, I., Shmelkov, S. V., Young, L. M., & Rafii, S. (2006). Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nature Medicine, 12(5), 557–567.
146. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., & Sica, A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 23(11), 549–555.
147. De Palma, M., Murdoch, C., Venneri, M. A., Naldini, L., & Lewis, C. E. (2007). Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends in Immunology, 28(12), 519–524.
148. Venneri, M. A., De Palma, M., Ponzoni, M., Pucci, F., Scielzo, C., Zonari, E., & Naldini, L. (2007). Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood, 109(12), 5276–5285.
149. Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., & Zitvogel, L. (2005). Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. The Journal of Experimental Medicine, 202(7), 919–929.
150. Nagaraj, S., & Gabrilovich, D. I. (2010). Myeloid-derived suppressor cells in human cancer. Cancer Journal, 16(4), 348–353.
151. Tazzyman, S., Niaz, H., & Murdoch, C. (2013). Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. Seminars in Cancer Biology, 23(3), 149–158.
152. Looi, L. M. (1987). Tumor-associated tissue eosinophilia in nasopharyngeal carcinoma. A pathologic study of 422 primary and 138 metastatic tumors. Cancer, 59(3), 466–470.
153. Reed, J. A., McNutt, N. S., Bogdany, J. K., & Albino, A. P. (1996). Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression. Journal of Cutaneous Pathology, 23(6), 495–505.
154. Griffioen, A. W., Damen, C. A., Blijham, G. H., & Groenewegen, G. (1996). Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood, 88(2), 667–673.
155. Griffioen, A. W., Tromp, S. C., & Hillen, H. F. (1998). Angiogenesis modulates the tumour immune response. International Journal of Experimental Pathology, 79(6), 363–368.
156. Tromp, S. C., oude Egbrink, M. G., Dings, R. P., van Velzen, S., Slaaf, D. W., Hillen, H. F., & Griffioen, A. W. (2000). Tumor angiogenesis factors reduce leukocyte adhesion in vivo. International Immunology, 12(5), 671–676.
157. Dirkx, A. E. M., Oude Egbrink, M. G. A., Kuijpers, M. J. E., van der Niet, S. T., Heijnen, V. V. T., Bouma-ter Steege, J. C. A., & Griffioen, A. W. (2003). Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Research, 63(9), 2322–2329.
158. Dirkx, A. E. M., Oude Egbrink, M. G. A., Wagstaff, J., & Griffioen, A. W. (2006). Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 80(6), 1183–1196.
159. Jain, R. K., & Booth, M. F. (2003). What brings pericytes to tumor vessels? The Journal of Clinical Investigation, 112(8), 1134–1136.
160. Abramsson, A., Lindblom, P., & Betsholtz, C. (2003). Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. The Journal of Clinical Investigation, 112(8), 1142–1151.
161. Koch, A. E., Halloran, M. M., Haskell, C. J., Shah, M. R., & Polverini, P. J. (1995). Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature, 376(6540), 517–519.
162. Fukushi, J., Ono, M., Morikawa, W., Iwamoto, Y., & Kuwano, M. (2000). The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13. Journal of Immunology, 165(5), 2818–2823.
163. Nakao, S., Kuwano, T., Ishibashi, T., Kuwano, M., & Ono, M. (2003). Synergistic effect of TNF-alpha in soluble VCAM-1-induced angiogenesis through alpha 4 integrins. Journal of Immunology, 170(11), 5704–5711.
164. Calzada, M. J., Zhou, L., Sipes, J. M., Zhang, J., Krutzsch, H. C., Iruela-Arispe, M. L., & Roberts, D. D. (2004). Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circulation Research, 94(4), 462–470.
165. Garmy-Susini, B., Jin, H., Zhu, Y., Sung, R.-J., Hwang, R., & Varner, J. (2005). Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. The Journal of Clinical Investigation, 115(6), 1542–1551.
166. Banerji, S., Ni, J., Wang, S. X., Clasper, S., Su, J., Tammi, R., & Jackson, D. G. (1999). LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. The Journal of Cell Biology, 144(4), 789–801.
167. Wigle, J. T., & Oliver, G. (1999). Prox1 function is required for the development of the murine lymphatic system. Cell, 98(6), 769–778.
168. Breiteneder-Geleff, S., Soleiman, A., Kowalski, H., Horvat, R., Amann, G., Kriehuber, E., & Kerjaschki, D. (1999). Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. The American Journal of Pathology, 154(2), 385–394.
169. Baluk, P., & McDonald, D. M. (2008). Markers for microscopic imaging of lymphangiogenesis and angiogenesis. Annals of the New York Academy of Sciences, 1131, 1–12.
170. Huang, X. Z., Wu, J. F., Ferrando, R., Lee, J. H., Wang, Y. L., Farese, R. V., Jr., & Sheppard, D. (2000). Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Molecular and Cellular Biology, 20(14), 5208–5215.
171. Mishima, K., Watabe, T., Saito, A., Yoshimatsu, Y., Imaizumi, N., Masui, S., & Miyazono, K. (2007). Prox1 induces lymphatic endothelial differentiation via integrin alpha9 and other signaling cascades. Molecular Biology of the Cell, 18(4), 1421–1429.
172. Bazigou, E., Xie, S., Chen, C., Weston, A., Miura, N., Sorokin, L., & Makinen, T. (2009). Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Developmental Cell, 17(2), 175–186.
173. Hong, Y.-K., Lange-Asschenfeldt, B., Velasco, P., Hirakawa, S., Kunstfeld, R., Brown, L. F., & Detmar, M. (2004). VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB Journal, 18(10), 1111–1113.
174. Grimaldo, S., Yuen, D., Ecoiffier, T., & Chen, L. (2011). Very late antigen-1 mediates corneal lymphangiogenesis. Investigative Ophthalmology & Visual Science, 52(7), 4808–4812.
175. Dietrich, T., Onderka, J., Bock, F., Kruse, F. E., Vossmeyer, D., Stragies, R., & Cursiefen, C. (2007). Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. The American Journal of Pathology, 171(1), 361–372.
176. Garmy-Susini, B., Avraamides, C. J., Schmid, M. C., Foubert, P., Ellies, L. G., Barnes, L., & Varner, J. A. (2010). Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Research, 70(8), 3042–3051.
177. Garmy-Susini, B., Makale, M., Fuster, M., & Varner, J. A. (2007). Methods to study lymphatic vessel integrins. Methods in Enzymology, 426, 415–438.
178. Zhou, F., Chang, Z., Zhang, L., Hong, Y.-K., Shen, B., Wang, B., & He, Y. (2010). Akt/Protein kinase B is required for lymphatic network formation, remodeling, and valve development. The American Journal of Pathology, 177(4), 2124–2133.
179. Garmy-Susini, B., Avraamides, C. J., Desgrosellier, J. S., Schmid, M. C., Foubert, P., Ellies, L. G., & Varner, J. (2013). PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes. Proceedings of the National Academy of Sciences of the United States of America, 110(22), 9042–9047.
180. Testaz, S., & Duband, J. L. (2001). Central role of the alpha4beta1 integrin in the coordination of avian truncal neural crest cell adhesion, migration, and survival. Developmental Dynamics, 222(2), 127–140.
181. Alvarez-Dolado, M. (2007). Cell fusion: biological perspectives and potential for regenerative medicine. Frontiers in Bioscience: a Journal and Virtual Library, 12, 1–12.
182. Nygren, J. M., Liuba, K., Breitbach, M., Stott, S., Thorén, L., Roell, W., & Jacobsen, S. E. W. (2008). Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. Nature Cell Biology, 10(5), 584–592.
183. Nygren, J. M., Jovinge, S., Breitbach, M., Säwén, P., Röll, W., Hescheler, J., & Jacobsen, S. E. W. (2004). Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nature Medicine, 10(5), 494–501.
184. Singec, I., & Snyder, E. Y. (2008). Inflammation as a matchmaker: revisiting cell fusion. Nature Cell Biology, 10(5), 503–505.
185. Mortensen, K., Lichtenberg, J., Thomsen, P. D., & Larsson, L.-I. (2004). Spontaneous fusion between cancer cells and endothelial cells. Cellular and Molecular life Sciences: CMLS, 61(16), 2125–2131.
186. Song, K., Zhu, F., Zhang, H., & Shang, Z. (2012). Tumor necrosis factor-α enhanced fusions between oral squamous cell carcinoma cells and endothelial cells via VCAM-1/VLA-4 pathway. Experimental Cell Research, 318(14), 1707–1715.
187. Durand, R. E., & Sutherland, R. M. (1972). Effects of intercellular contact on repair of radiation damage. Experimental Cell Research, 71(1), 75–80.
188. Fridman, R., Giaccone, G., Kanemoto, T., Martin, G. R., Gazdar, A. F., & Mulshine, J. L. (1990). Reconstituted basement membrane (Matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America, 87(17), 6698–6702.
189. Meredith, J. E., Jr., Fazeli, B., & Schwartz, M. A. (1993). The extracellular matrix as a cell survival factor. Molecular Biology of the Cell, 4(9), 953–961.
190. Schuetz, J. D., & Schuetz, E. G. (1993). Extracellular matrix regulation of multidrug resistance in primary monolayer cultures of adult rat hepatocytes. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research, 4(1), 31–40.
191. Bates, R. C., Buret, A., van Helden, D. F., Horton, M. A., & Burns, G. F. (1994). Apoptosis induced by inhibition of intercellular contact. The Journal of Cell Biology, 125(2), 403–415.
192. Scott, G., Cassidy, L., & Busacco, A. (1997). Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism. The Journal of Investigative Dermatology, 108(2), 147–153.
193. Bradstock, K. F., & Gottlieb, D. J. (1995). Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leukemia & Lymphoma, 18(1–2), 1–16.
194. St Croix, B., & Kerbel, R. S. (1997). Cell adhesion and drug resistance in cancer. Current Opinion in Oncology, 9(6), 549–556.
195. Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., & Niitsu, Y. (2003). Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nature Medicine, 9(9), 1158–1165.
196. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., & Dalton, W. S. (1999). Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93(5), 1658–1667.
197. Mori, Y., Shimizu, N., Dallas, M., Niewolna, M., Story, B., Williams, P. J., & Yoneda, T. (2004). Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood, 104(7), 2149–2154.
198. Park, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J., & Bissell, M. J. (2006). Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Research, 66(3), 1526–1535.
199. Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009). Environment-mediated drug resistance: a major contributor to minimal residual disease. Nature Reviews Cancer, 9(9), 665–674.
200. Chen, Y.-X., Wang, Y., Fu, C.-C., Diao, F., Song, L.-N., Li, Z.-B., & Lu, J. (2010). Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Endocrine-Related Cancer, 17(1), 39–50.
201. Scalici, J. M., Harrer, C., Allen, A., Jazaeri, A., Atkins, K. A., McLachlan, K. R., & Slack-Davis, J. K. (2014). Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin. Gynecologic Oncology, 132(2), 455–461.
202. Weekes, C. D., Pirruccello, S. J., Vose, J. M., Kuszynski, C., & Sharp, J. G. (1998). Lymphoma cells associated with bone marrow stromal cells in culture exhibit altered growth and survival. Leukemia & Lymphoma, 31(1–2), 151–165.
203. Weekes, C. D., Kuszynski, C. A., & Sharp, J. G. (2001). VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells. Leukemia & Lymphoma, 40(5–6), 631–645.
204. St Croix, B., Flørenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M., & Kerbel, R. S. (1996). Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nature Medicine, 2(11), 1204–1210.
205. Fukai, F., Mashimo, M., Akiyama, K., Goto, T., Tanuma, S., & Katayama, T. (1998). Modulation of apoptotic cell death by extracellular matrix proteins and a fibronectin-derived antiadhesive peptide. Experimental Cell Research, 242(1), 92–99.
206. Ilić, D., Almeida, E. A., Schlaepfer, D. D., Dazin, P., Aizawa, S., & Damsky, C. H. (1998). Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. The Journal of Cell Biology, 143(2), 547–560.
207. Damiano, J. S., & Dalton, W. S. (2000). Integrin-mediated drug resistance in multiple myeloma. Leukemia & Lymphoma, 38(1–2), 71–81.
208. Higashimoto, I., Chihara, J., Kakazu, T., Kawabata, M., Nakajima, S., & Osame, M. (1996). Regulation of eosinophil cell death by adhesion to fibronectin. International Archives of Allergy and Immunology, 111(Suppl 1), 66–69.
209. De la Fuente, M. T., Casanova, B., Garcia-Gila, M., Silva, A., & Garcia-Pardo, A. (1999). Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia, 13(2), 266–274.
210. Konopleva, M., Konoplev, S., Hu, W., Zaritskey, A. Y., Afanasiev, B. V., & Andreeff, M. (2002). Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia, 16(9), 1713–1724.
211. Liu, C.-C., Leclair, P., Yap, S. Q., & Lim, C. J. (2013). The membrane-proximal KXGFFKR motif of α-integrin mediates chemoresistance. Molecular and Cellular Biology, 33(21), 4334–4345.
212. Layani-Bazar, A., Skornik, I., Berrebi, A., Pauker, M. H., Noy, E., Silberman, A., & Sredni, B. (2014). Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state. Cancer Research. doi:10.1158/0008-5472.CAN-13-2159.
213. Jacamo, R., Chen, Y., Wang, Z., Ma, W., Zhang, M., Spaeth, E. L., & Andreeff, M. (2014). Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood, 123(17), 2691–2702.
214. Brachtl, G., Piñón Hofbauer, J., Greil, R., & Hartmann, T. N. (2014). The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Annals of Hematology, 93(3), 361–374.
215. Gattei, V., Bulian, P., Del Principe, M. I., Zucchetto, A., Maurillo, L., Buccisano, F., & Del Poeta, G. (2008). Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood, 111(2), 865–873.
216. Nückel, H., Switala, M., Collins, C. H., Sellmann, L., Grosse-Wilde, H., Dührsen, U., & Rebmann, V. (2009). High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clinical Immunology, 131(3), 472–480.
217. Balcer, L. J., Galetta, S. L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Havrdova, E., & Panzara, M. A. (2007). Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology, 68(16), 1299–1304.
218. Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., & Hyde, R. (2009). Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. The Lancet. Neurology, 8(3), 254–260.
219. Armuzzi, A., & Felice, C. (2013). Natalizumab in Crohn’s disease: past and future areas of applicability. Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology, 26(3), 189–190.
220. Lanzarotto, F., Carpani, M., Chaudhary, R., & Ghosh, S. (2006). Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin. Drugs, 66(9), 1179–1189.
221. Polman, C. H., O’Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., & Investigators, A. F. F. I. R. M. (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. The New England Journal of Medicine, 354(9), 899–910.
222. Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., & Investigators, S. E. N. T. I. N. E. L. (2006). Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. The New England Journal of Medicine, 354(9), 911–923.
223. Berger, J. R., & Houff, S. (2006). Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurological Research, 28(3), 299–305.
224. Tur, C., & Montalban, X. (2014). Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs, 28(7), 641–648.
225. Cutter, G. R., & Stüve, O. (2014). Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Multiple Sclerosis, 20(10), 1304–1305.
226. Vavricka, B. M. P., Baumberger, P., Russmann, S., & Kullak-Ublick, G. A. (2011). Diagnosis of melanoma under concomitant natalizumab therapy. Multiple Sclerosis, 17(2), 255–256.
227. Mullen, J. T., Vartanian, T. K., & Atkins, M. B. (2008). Melanoma complicating treatment with natalizumab for multiple sclerosis. The New England Journal of Medicine, 358(6), 647–648.
228. Olson, D. L., Burkly, L. C., Leone, D. R., Dolinski, B. M., & Lobb, R. R. (2005). Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Molecular Cancer Therapeutics, 4(1), 91–99.
229. Podar, K., Zimmerhackl, A., Fulciniti, M., Tonon, G., Hainz, U., Tai, Y.-T., & Anderson, K. C. (2011). The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. British Journal of Haematology, 155(4), 438–448.
230. Study of Natalizumab in Relapsed/Refractory Multiple Myeloma - ClinicalTrials.gov. (n.d.). Retrieved August 28, 2014, from https://clinicaltrials.gov/ct2/show/NCT00675428
231. Ramirez, P., Rettig, M. P., Uy, G. L., Deych, E., Holt, M. S., Ritchey, J. K., & DiPersio, J. F. (2009). BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood, 114(7), 1340–1343.
232. Rettig, M. P., Ansstas, G., & DiPersio, J. F. (2012). Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia, 26(1), 34–53.
233. Davenport, R. J., & Munday, J. R. (2007). Alpha4-integrin antagonism—an effective approach for the treatment of inflammatory diseases? Drug Discovery Today, 12(13–14), 569–576.
234. Davenport, R. J., & Munday, J. R. (2008). Blocking alpha4-integrins—a small molecule approach to treatment of multiple sclerosis. Journal of the Neurological Sciences, 274(1–2), 27–30.
235. Schmid, M. C., Avraamides, C. J., Foubert, P., Shaked, Y., Kang, S. W., Kerbel, R. S., & Varner, J. A. (2011). Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Research, 71(22), 6965–6975.
236. Schlesinger, M., Roblek, M., Ortmann, K., Naggi, A., Torri, G., Borsig, L., & Bendas, G. (2014). The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. Thrombosis Research, 133(5), 855–862.